Welcome to SynAging SAS

Your R&D partner for in vitro and in vivo phenotypic models in WT, accelerating drug discovery for sporadic neurodegenerative diseases.

News

SynAging has new phone and fax numbers in 2017! Please amend your records accordingly. The old numbers will work until the end of 2017 only!

SynAging will be present at the following meetings in 2017:

European Brain & Behavior Society Meeting, September 8-11, Bilbao, Spain

Neuroscience R&D Technologies Conference, September 28-29, London, UK - Presentation on Sept. 29

Genesis Drug Discovery, October 11-12, Frankfurt, Germany - Presentation on Oct. 11

BIO-Europe 2017, November 6-8, Berlin, Germany

BioFIT 2017, November 28-29, Strassbourg, France, meet us at booth C4

SynAging' past meetings in 2017:

EuroTau Meeting, April 27-28, Lille, France

International Conference on Alzheimer's & Parkinson’s Diseases 2017 - Booth 14a, at the entrance of the exhibition & Posters
March 29 . – April 2., Vienna, Austria

SynAging's past meetings in 2016:

Press & Publications

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy
www.ncbi.nlm.nih.gov/pubmed/28623233

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease
promisneurosciences.com/uncategorized/promis-neurosciences-designates-pmn350-second-lead-product-development-alzheimers-disease/

HUMAN TAU OLIGOMERS INDUCE NEURODEGENERATION: TAUOPATHY MODELS FOR TARGET VALIDATION AND DRUG DEVELOPMENT
Download PDF

HUMAN ALPHA-SYNUCLEIN OLIGOMERS BUT NOT 'SPREADING' FIBRILS INDUCE EARLY COGNITIVE DECLINE IN MICE
Download PDF

SynAging's human tau oligomer poster at SFN 2016
Download PDF

SynAging's alpha synuclein oligomer poster at SFN 2016
Download PDF

SynAging's Alzheimers disease poster at AAIC 2016
Download PDF

SynAging's Parkinson's disease poster at AAIC 2016
Download PDF

 

Management

 

Violette Koziel, President

VioletteKoziel, CEOViolette is a co-founder of SynAging and manages all operational and financial aspects of the company.

She has gained more than 25 years of operational and research experience in neurosciences at Inserm (Institut National de la Santé et de la Recherche Médicale).

At Inserm she managed five different labs and had full budgetary responsibility. Within her scientific career Violette has co-published 49 peer-reviewed publications in neurobiology.

 

 

Thierry Pillot, PhD, CEO / CSO

Dr. Thierry Pillot, CSOSince 2010 Thierry is leading the scientific planning and quality performance of projects and services by SynAging. He has worked as a research scientist for more than 20 years, mainly in the area of neurodegenerative diseases. He specialized in the structural aspects of disease relevant proteins, their structure, aggregation and interactions with cellular targets in the lipid membrane. Thierry has published 44 peer-reviewed publications.

Before co-founding SynAging, Thierry specialized in neurosciences at Jean Chambaz ’ lab, at Inserm, in Paris, and became the director of the “Lipids and Neurodegeneration in Alzheimer’s disease” group at the Lorraine University, Nancy. During his post-doctoral time at Joel Vandekerkhove’s lab in Gent, he specialized in the biophysical aspects of protein function combining molecular modeling and experimental approaches. Thierry earned his PhD in biochemistry at the University of “Nancy 1”, Dept. of Molecular and Cellular Biology, and holds a degree in biochemistry and enzymology from the same university

 

Dr. Andreas Köpke, Chief Business Officer

Dr. Andreas KöpkeHas 20 years of experience in the pharmaceutical and biotech industry in various executive roles. His scientific and drug development proficiency in the neurodegenerative disease field combined with his business development and managerial experience supported SynAging since 2012 to become a preferred service partner with international biotech and pharma companies. Please feel free to contact Andreas directly if you have any questions regarding SynAging’s services. Andreas.Kopke@SynAging.com.